These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449 [TBL] [Abstract][Full Text] [Related]
9. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ; Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955 [TBL] [Abstract][Full Text] [Related]
11. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial. Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL; Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730 [TBL] [Abstract][Full Text] [Related]
12. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P; J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829 [TBL] [Abstract][Full Text] [Related]
13. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Pettit AC; Phillips PPJ; Kurbatova E; Vernon A; Nahid P; Dawson R; Dooley KE; Sanne I; Waja Z; Mohapi L; Podany AT; Samaneka W; Savic RM; Johnson JL; Muzanyi G; Lalloo UG; Bryant K; Sizemore E; Scott N; Dorman SE; Chaisson RE; Swindells S; Clin Infect Dis; 2023 Feb; 76(3):e580-e589. PubMed ID: 36041016 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536 [TBL] [Abstract][Full Text] [Related]
15. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Svensson EM; Aweeka F; Park JG; Marzan F; Dooley KE; Karlsson MO Antimicrob Agents Chemother; 2013 Jun; 57(6):2780-7. PubMed ID: 23571542 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132 [TBL] [Abstract][Full Text] [Related]
17. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Swindells S; Ramchandani R; Gupta A; Benson CA; Leon-Cruz J; Mwelase N; Jean Juste MA; Lama JR; Valencia J; Omoz-Oarhe A; Supparatpinyo K; Masheto G; Mohapi L; da Silva Escada RO; Mawlana S; Banda P; Severe P; Hakim J; Kanyama C; Langat D; Moran L; Andersen J; Fletcher CV; Nuermberger E; Chaisson RE; N Engl J Med; 2019 Mar; 380(11):1001-1011. PubMed ID: 30865794 [TBL] [Abstract][Full Text] [Related]
18. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F; Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830 [TBL] [Abstract][Full Text] [Related]
19. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Francis J; Mngqibisa R; McIlleron H; Kendall MA; Wu X; Dooley KE; Firnhaber C; Godfrey C; Cohn SE; Denti P; Clin Pharmacol Ther; 2021 Oct; 110(4):1057-1065. PubMed ID: 34151439 [TBL] [Abstract][Full Text] [Related]
20. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342 [No Abstract] [Full Text] [Related] [Next] [New Search]